NCT02876718View on ClinicalTrials.gov

Xarelto Evidence in Real Life of Patients' Preference and Satisfaction Study

CompletedOBSERVATIONAL
Enrollment

253

Participants

Timeline

Start Date

August 11, 2016

Primary Completion Date

January 9, 2018

Study Completion Date

January 9, 2018

Conditions
Atrial Fibrillation
Interventions
DRUG

Rivaroxaban (Xarelto, BAY 59-7939)

No specified dosing or dosage in the study. The treatment decision falls within current practice and the prescription of the medicines is clearly separated from the decision to include the patient in the study.

Trial Locations (1)

Unknown

Many Locations, Multiple Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
collaborator

Janssen Research & Development, LLC

INDUSTRY

lead

Bayer

INDUSTRY

NCT02876718 - Xarelto Evidence in Real Life of Patients' Preference and Satisfaction Study | Biotech Hunter | Biotech Hunter